Greetings!

We invite you to attend the 2010 Breast Cancer | New Horizons | Current Controversies, a three-day course jointly sponsored by Harvard Medical School, Dana-Farber/Brigham and Women’s Cancer Center, and Massachusetts General Hospital Cancer Center.

This is our 9th year leading this international course, which annually attracts 350-400 oncology clinicians. During that time, the quality of our faculty has been consistently rated above average in terms of educational content, presentation, and relevance to practice. Last year, 99% of our learners told us the course provided the most up-to-date information that could be immediately translated into their practices, while 92% rated the course above average or superior to other post-graduate courses.

We understand that time constraints and economic considerations mean you're being more selective than ever when planning your continuing education. That’s why we recently conducted a needs-assessment study with many of you. Based on your input, everything about this course, from the curriculum to the accommodations, has been designed to give you the greatest possible value.

This year’s curriculum will address seven key learning objectives:

1. Review breast cancer risk factors and the controversies related to screening
2. Examine pre-operative therapy challenges
3. Understand the evolving approaches to pre-invasive disease
4. Examine the latest protocols for determining who benefits from adjuvant and neoadjuvant therapies; anticipate, identify, and manage side e"ects in order to improve patients’ quality of life and compliance
5. Explore the current surgical options for patients with breast cancer or increased risk
6. Discuss the molecular heterogeneity of breast cancer and its therapeutic implications
7. Review and discuss emerging clinical trial results on multiple aspects of breast cancer diagnosis, management, and treatment selected by experts as having practical application to current clinical practice

The course will also feature more opportunities for specialized learning and personal interactions between faculty and learners:

• Concurrent small group work sessions and discussion groups that address specific clinical challenges.
• Challenging, multidisciplinary case studies and tumor panels to facilitate the exchange of best practices.
• A presentation of highlights from ASCO, followed by a discussion of the practice implications.
• 59 world-renown faculty

Because we believe our learners benefit from a "campus-like" experience, we have negotiated a special rate with our hotel partner, the brand new Renaissance Boston Waterfront Hotel—$185 per night, $100 less than last year. We’ve also added a cocktail reception with faculty on Thursday evening and will be providing lunch on Friday.

We hope you'll join us this July. We think you'll find our course to be a unique and valuable learning experience.

Please register early as seats!are limited and the course fills up quickly.

Best,

Judy E. Garber, MD, MPH
Director, Friends Cancer Risk and Prevention Clinic,
Dana-Farber Cancer Institute

Barbara L. Smith, MD, PhD
Director, Gillette Center for Breast Cancer,
Massachusetts General Hospital Cancer Center

Eric P. Winer, MD
Thompson Senior Investigator and Chief,
Division of Women’s Cancers, Dana-Farber Cancer Institute

NEEDS ASSESSMENT SURVEY

The design of this year’s course and the development of our learning objective were derived from the results of a needs assessment study with our target learners. The study highlights both knowledge and practice gaps of our specific target learners, to review the results of the self-assessment study just visit: http://cme.med.harvard.edu/cmeups/pdf/00301279_NeedsAssessmentSurvey.pdf.

Last update 03.08.10

OBJECTIVE

• Review breast cancer risk factors and the controversies related to screening
• Examine pre-operative therapy challenges
• Understand the evolving approaches to pre-invasive disease
• Examine the latest protocols for determining who benefits from adjuvant and neoadjuvant therapies; anticipate, identify, and manage side e"ects in order to improve patients’ quality of life and compliance
• Explore the current surgical options for patients with breast cancer or increased risk
• Discuss the molecular heterogeneity of breast cancer and its therapeutic implications
• Review and discuss emerging clinical trial results on multiple aspects of breast cancer diagnosis, management, and treatment selected by experts as having practical application to current clinical practice.

ADVANCES. CHALLENGES.

Revolutionary advances in cell biology, genetics, neoadjuvant treatment strategies, and surgical techniques are o"ering new options for diagnosing, treating, and overcoming breast cancer. Jointly sponsored by Harvard Medical School, Dana-Farber/Brigham and Women’s Cancer Center, and Massachusetts General Hospital Cancer Center, this three-day course provides the most up-to-date, in-depth focus on this disease—from its pathogenesis to the economics of breast care health.

WORLD-CLASS FACULTY. MULTIDISCIPLINARY APPROACH.

The course offers a rare gathering of world-class educators in medical, surgical, and radiation oncology who will discuss challenging clinical cases, address controversial topics, and offer practical treatment strategies. Using a multidisciplinary approach, the course will enable you to:

• Become acquainted with the latest disease research, medications, therapies, and clinical trials, and the implications for your practice.
• Have the opportunity for one-to-one conversations about your clinical challenges.
• Learn about the key findings from the 2010 ASCO conference.
• Engage faculty in a range of settings, including small group courses, panel discussions, challenging case discussions, one-to-one conversations, and networking.

TARGET LEARNERS

Medical oncologists, surgical oncologists, radiation oncologists, breast surgeons, internists, physician’s assistants, nurse practitioners, oncology nurses, breast cancer advocates and others interested in the care of women with breast cancer.

COMMERCIAL SUPPORT

The conference organizers are applying for unrestricted educational grants in support of this program. The list of contributors will be provided at the conference. All Harvard Medical School programs are organized solely to promote the exchange and dissemination of scientific and medical information. No promotional content is permitted.

There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers, and do not represent an endorsement or recommendation on the part of Harvard Medical School.

No cameras, tape recorders, or other recording devices are permitted in the meeting room.

Name badges will be provided onsite and, for security reasons, are required for admission to all sessions.

NEW THIS YEAR

• Concurrent small group work sessions and discussions on clinical challenges
• 2010 ASCO highlights
• Eight panel discussions with Q&As
• Two workshops on challenging multidisciplinary cases
• Cocktail reception with faculty Thursday evening and work session with complimentary lunch on Friday
• Brand new hotel venue with special $185 room rate - $100 savings over last year
• Earn up to 20.75 AMA PRA Category 1 Credit(s)™

Attendance Limited

No time to register now? Add your name to the mailing list to receive future notices about this course!
Email Address:

BREAST CANCER: CURRENT CONTROVERSIES AND NEW HORIZONS
Renaissance Boston Waterfront Hotel

THURSDAY, JULY 15, 2010
7:15	Registration and Continental Breakfast
8:00	Welcoming Remarks Eric P. Winer, MD, Dana-Farber/Brigham and Women’s Cancer Center
8:10	Jean H. Lubrano Distinguished Visiting Scholar Lecture The Role of PARP Inhibition in Breast Cancer Treatment Andrew Tutt, MRCP, FRCR, PhD, Kings College London School of Medicine
SESSION I –  RISK AND SCREENING Moderator: Judy E. Garber, MD, MPH, Dana-Farber/Brigham and Women’s Cancer Center
8:50	Modifiable Breast Risk Factors: Alcohol, Diet, and Exercise Wendy Y. Chen, MD, Dana-Farber/Brigham and Women’s Cancer Center
9:10	BRCA1, 2 and Beyond Susan M. Domcheck, MD, University of Pennsylvania Rena Rowan Breast Center
9:30	The Mammographic Screening Controversy Ellen Warner, MD, FRCPC, FACP, M.Sc., Sunnybrook Research Institute, Toronto, ON
10:00	Panel Discussion with Q&A
10:20	Break
SESSION II –  PRE-INVASIVE DISEASE Moderator: Kevin S. Hughes, MD, Massachusetts General Hospital Cancer Center
10:40	Are We Over-Diagnosing Pre-Invasive Disease? Laura Esserman, MD, MBA, Univeristy of California, San Francisco
11:00	The Pathology of DCIS and Other Pre-Invasive Lesions Laura C. Collins, MD, Beth Israel Deaconess Medical Center
11:20	Modern Surgical Approaches to DCIS Mehra Golshan, MD, FACS, Dana-Farber/Brigham and Women’s Cancer Center
11:40	Do All Patients with DCIS Need Radiation After Conservative Surgery? Julia Wong, MD, Dana-Farber/Brigham and Women’s Cancer Center
12:00	Panel Discussion with Q&A
12:20	Break (Lunch on your own)
1:30	Challenging Cases –  Early Stage Disease Moderator: Craig A. Bunnell, MD, MBA Dana-Farber/Brigham and Women’s Cancer Center Panelists: Elizabeth Rafferty, MD, Massachusetts General Hospital Jane Brock, MD, Brigham and Women’s Hospital Michele A. Gadd, MD, Massachusetts General Hospital Cancer Center Rinaa Punglia, MD, Dana-Farber/Brigham and Women’s Cancer Center Eric P. Winer, MD, Dana-Farber/Brigham and Women’s Cancer Center Steven J. Isako3, MD, PhD, Massachusetts General Hospital Cancer Center
SESSION III –  CHALLENGES IN PREOPERATIVE THERAPY Moderator: J. Dirk Iglehart, MD, Dana-Farber/Brigham and Women’s Cancer Center
2:30	Identifying Candidates for Preoperative Therapy J. Dirk Inglehart, MD, Dana-Farber/Brigham and Women’s Cancer Center
2:50	Preoperative Therapy for Triple Negative Disease Judy E. Garber, MD, MPH, Dana-Farber/Brigham and Women’s Cancer Center
3:10	Preoperative Therapy for HER2+ Disease Lyndsay Harris, MD, Yale University School of Medicine
3:30	Preoperative Therapy for ER+ Disease Matthew Ellis, MD, Washington University
3:50	Panel Discussion with Q&A
4:10	Break
4:30	Imaging the Patient Receiving Preoperative Therapy Eren Yeh, MD, Dana-Farber/Brigham and Women’s Cancer Center
4:50	Pathology Assessment After Preoperative Therapy Andrea Richardson, MD, PhD, Dana-Farber/Brigham and Women’s Cancer Center
5:10	Surgery Issues After Preoperative Therapy Funda Meric-Berstram, MD, MD Anderson Cancer Center
5:30	Radiation Therapy Challenges After Preoperative Therapy Jennifer Bellon, MD, Dana-Farber/Brigham and Women’s Cancer Center
5:50	Panel Discussion with Q&A
6:10	Closing Remarks
6:15	Complimentary wine and cheese reception with faculty
FRIDAY, JULY 16, 2010
6:30	Continental Breakfast
7:30	Concurrent Small Group Work Sessions And Discussions On Clinical Challenges Please indicate your top three choices in order of preference when registering for the course. A. Enhancing Supportive Care for Our Patients Jennifer Belmonte, Surgical PA, Massachusetts General Hospital Cancer Center Georgia Litsas, NP, Dana-Farber/Brigham and Women’s Cancer Center Note: This concurrent session is designed specifically for NPs, PAs, and RNs B. Managing the Extra-Axillary Sentinel Node and Positive Internal Mammary Nodes Funda Meric-Berstram, MD, MD Anderson Cancer Center C. Role of Surgery in Stage IV Disease Susan Troyan, MD, Dana-Farber/Brigham and Women’s Cancer Center Sara Tolaney, MD, MPH, Dana-Farber/Brigham and Women’s Cancer Center D. Partial Breast Irradiation Shannon MacDonald, MD, Massachusetts General Hospital Cancer Center E. Bisphosphonates in the Adjuvant Setting Julie Gralow, MD, Seattle Cancer Care Alliance F. Special Considerations for Managing Breast Cancer in Young Women Ann Partridge, MD, MPH, Dana-Farber/Brigham and Women’s Cancer Center and Lidia Schapira, MD, Massachusetts General Hospital Cancer Center G. New Targets for Triple Negative Breast Cancer Daniel P. Silver, MD, PhD, Dana-Farber/Brigham and Women’s Cancer Center H. Adjuvant Treatment in the Elderly Mike Hassett, MD, MPH, Dana-Farber/Brigham and Women’s Cancer Center Rachel Freedman, MD, MPH, Dana-Farber/Brigham and Women’s Cancer Center I. Managing Menopausal Symptoms Jennifer A. Ligibel, MD, Dana-Farber/Brigham and Women’s Cancer Center J. Incorporating Genetics into Oncology Practice Susan M. Domcheck, MD, University of Pennsylvania Rena Rowan Breast Center K. CYP2D6 Testing Kathryn Ruddy, MD, MPH, Dana-Farber/Brigham and Women’s Cancer Center Harold J. Burstein, MD, PhD, Dana-Farber/Brigham and Women’s Cancer Center L. Immunotherapy for Breast Cancer Karen S. Anderson, MD, PhD, Dana-Farber/Brigham and Women’s Cancer Center
8:30	Judith P. Schlager Lecture Advances in Radiation Oncology Alain Fourquet, MD, Institut Curie, Paris, France
9:30	Break
SESSION IV –  ADVANCED BREAST CANCER Moderator: Eric P. Winer, MD, Dana-Farber/Brigham and Women’s Cancer Center
9:50	What Outcomes Matter in Clinical Trials in Metastatic Disease Nancy U. Lin, MD, Dana-Farber/Brigham and Women’s Cancer Center
10:10	HER2+ Breast Cancer: The Present and Future Ian E. Krop, MD, PhD, Dana-Farber/Brigham and Women’s Cancer Center
10:30	How Can We Improve Endocrine Therapy for Advanced Breast Cancer C. Kent Osborne, MD, Baylor Cancer Center
10:50	Angiogenesis Inhibitors: A Major Advance? Erica Mayer, MD, MPH, Dana-Farber/Brigham and Women’s Cancer Center
11:10	Tumor Heterogeneity: The Real Challenge Kornelia Polyak, MD, PhD, Dana-Farber Cancer Institute
11:45	Panel Discussion with Q&A
12:15	Break
12:30	Lunch Served Challenging Multidisciplinary Cases –  Early Stage and Advanced Disease Moderator: Harold J. Burstein, MD, PhD, Dana-Farber/Brigham and Women’s Cancer Center Panelists: Melinda Lerwill, MD, Massachusetts General Hospital Cancer Center Jennifer McKenna, NP, Dana-Farber/Brigham and Women’s Cancer Center Jay Harris, MD, Dana-Farber/Brigham and Women’s Cancer Center Monica Morrow, MD, FACS, Memorial Sloan-Kettering Cancer Center Paula Ryan, MD, Massachusetts General Hospital Cancer Center Jerry Younger, MD, Massachusetts General Hospital Cancer Center
1:45 21	Break
SESSION V –  ADVANCES AND CONTROVERSIES IN LOCAL THERAPY Moderator: Michelle C. Specht, MD, Massachusetts General Hospital Cancer Center
2:00 21	Innovation in Lumpectomy and Mastectomy Surgery Barbara L. Smith, MD, PhD, Massachusetts General Hospital Cancer Center
2:20 21	Surgical Management of the Patient with a Positive Sentinel Node Susan Troyan, MD, Dana-Farber/Brigham and Women’s Cancer Center
2:40 21	Post-Mastectomy Radiation for Fewer than Four Nodes Jay R. Harris, MD, Dana-Farber/Brigham and Women’s Cancer Center
3:00 21	Breast Reconstruction: Which Option for Which Patient? Stephanie Caterson, MD, Brigham and Women’s Hospital
3:20 21	Can We Reverse the Trend Toward Bilateral Mastectomies? Monica Morrow, MD, FACS, Memorial Sloan-Kettering Cancer Center
3:40 21	Panel Discussion with Q&A
4:00 21	Break
4:20 21	New England Journal Of Medicine Clinicopathological Conference Patient with Inflammatory Breast Cancer Moderator: Nancy Lee Harris, MD, Massachusetts General Hospital Discussant: Beth Overmoyer, MD, Dana-Farber/Brigham and Women’s Cancer Center
5:20 21	Closing Remarks and Adjourn –  Day 2
SATURDAY, JULY 17, 2010
7:15	Continental Breakfast
8:00	Susan E. Donelan "hope For The Future" Lecture A Balancing Act: Comparative Effectiveness vs. Efficacy and the Cancer Research Agenda Deborah Schrag, MD, Dana-Farber/Brigham and Women’s Cancer Center
SESSION VI –  CONTROVERSIES AND UPDATE
8:45	ASCO Update Harold J. Burstein, MD, PhD, Dana-Farber/Brigham and Women’s Cancer Center
SESSION VII –  ADJUVANT THERAPY Moderator: Barbara L. Smith, MD, PhD, Massachusetts General Hospital Cancer Center
9:15	Which Patients Don't Need Chemotherapy? Julie Gralow, MD, Seattle Cancer Care Alliance
9:35	Picking the Optimal Adjuvant Endocrine Therapy for Post-Menopausal Women William J. Gradishar, MD, Robert H. Lurie Comprehensive Cancer Center
9:55	Picking the Optimal Adjuvant Endocrine Therapy for Pre-Menopausal Women Ann Partridge, MD, MPH, Dana-Farber/Brigham and Women’s Cancer Center
10:15	Break
10:30	Frontiers in the Adjuvant Treatment of HER2+ Disease Eric P. Winer, MD, Dana-Farber/Brigham and Women’s Cancer Center
10:50	Picking the Optimal Adjuvant Chemotherapy Regimen Giuseppe Curigliano, MD, European Institute of Oncology, Milan, Italy
11:10	Minimizing Toxicity of Adjuvant Therapy: Symptom Management Charles Loprinzi, MD, Mayo Clinic
11:30	Panel Discussion with Q&A
12:15	Concluding Remarks and Adjourn Eric P. Winer, MD, Dana-Farber/Brigham and Women’s Cancer Center

ACCREDITATION

Physician: Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Harvard Medical School designates this educational activity for a maximum of 20.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurse: Nursing continuing education hours (20.75) have been requested. Dana-Farber Cancer Institute is an approved provider of continuing nursing education by the Massachusetts Association of Registered Nurses, Inc., an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

REGISTRATION INFORMATION

Full Tuition (Registrations postmarked after May 1, 2010)
Physicians: $600 (USD)
Nurse Practitioners, Nurses, and Allied Health Professionals: $500 (USD)
Residents/Fellows in Training: $425 (USD)

* A letter of verification from Department Chairman must accompany registration form/payment for a reduced fee for Residents/ Fellows in Training.

All foreign payments must be made by a draft on a United States Bank or by Visa or MasterCard.

If paying by CHECK, please make payable to Harvard Medical School and mail with completed registration form to Harvard Medical School‑Department of Continuing Education, PO Box 825, Boston, MA 02117‑0825.

If paying by credit card, please register online here.

Telephone or mail‑in registration with credit card payment is not accepted.

Inquiries should be directed to the above address, made by phone: (617) 384‑8600, Monday ‑ Friday, 10 AM to 4 PM (EST), or by email: hms‑cme@hms.harvard.edu

Upon receipt of your registration form an email confirmation from the HMS-DCE office will be sent to you. Therefore, be sure to include an email address that you check daily/frequently. Your email address is used for critical information about the course including: registration confirmation, course evaluation and certificate.

TUITION REFUND POLICY

A handling fee of $60 is deducted for cancellation. Refund requests must be received by mail one week prior to the course. No refunds will be made thereafter.

COURSE LOCATION

Renaissance Boston Waterfront Hotel
Renaissance Boston Waterfront
606 Congress Street, Boston, MA 02210
617-338-4111
www.renaissanceboston.com

ACCOMMODATIONS

The new Renaissance Boston Waterfront Hotel is offering a special room rate of $185 per night.

With its convenient downtown Boston location, spectacular waterfront views, and luxurious amenities and services, the newly opened Renaissance Boston Waterfront Hotel provides an exceptional setting for our course. A limited block of rooms has been reserved for a special rate of $185/night (deluxe room, USD plus applicable tax, currently 14.45%).

Call 617-338-4111 or visit: https://resweb.passkey.com/go/knowledgetopractice for online reservations. Please identify yourself as a "Breast Cancer Course" attendee to receive the reduced room rate. Rooms are limited, so please book early.

TRAVEL

Please do not make non-refundable airline reservations until you have been confirmed into your course. You can make your airline reservation by calling the HMS Travel Desk toll free 1(877) 4-HARVMD (1-877-442-7863) Monday - Friday 9 AM - 8 PM (EST). From outside the U.S., Canada and Virgin Islands, please call (617) 559-3764.

---

Harvard Faculty
	Karen S. Anderson, MD, PhD Instructor in Medicine, Harvard Medical School; Medical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
	Jennifer Bellon, MD Assistant Professor of Radiation Oncology, Harvard Medical School; Radiation Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
	Jennifer Belmonte, PA Surgical PA, MGH Cancer Center
	Jane E. Brock, MD, BcH, PhD Instructor in Pathology, Harvard Medical School; Pathologist, Dana-Farber/Brigham and Women’s Cancer Center
	Craig A. Bunnell, MD, MPH, MBA Associate Chief Medical Officer, Dana-Farber Cancer Institute; Assistant Professor of Medicine; Harvard Medical School
	Harold J. Burstein, MD, PhD Associate Professor of Medicine, Harvard Medical School; Medical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
	Stephanie Caterson, MD Instructor in Surgery, Harvard Medical School; Surgeon, Brigham and Women’s Hospital
	Wendy Y. Chen, MD Assistant Professor of Medicine, Harvard Medical School; Medical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
	Laura Collins, MD Assistant Professor of Pathology, Harvard Medical School; Associate Director, Division of Anatomic Pathology, Beth Israel Deaconess Medical Center
	Rachel Freedman, MD, MPH Instructor in Medicine, Harvard Medical School; Medical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
	Michelle Gadd, MD Assistant Professor of Surgery, Harvard Medical School; Surgical Oncologist, Massachusetts General Hospital Cancer Center
	Judy E. Garber, MD, MPH Associate Professor of Medicine, Harvard Medical School; Director, Friends Cancer Risk and Prevention Clinic, Dana-Farber/Brigham and Women’s Cancer Center
	Mehra Golshan, MD, FACS Assistant Professor of Surgery, Harvard Medical School; Director of Breast Surgical Services, Dana-Farber/Brigham and Women’s Cancer Center
	Jay R. Harris, MD Professor and Chair, Department of Radiation Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School
	Nancy Lee Harris, MD Austin L. Vickey Professor of Pathology, Harvard Medical School; Pathologist, Director of Hematopathology, Massachusetts General Hospital; Editor, Case Records of the Massachusetts General Hospital, New England Journal of Medicine
	Michael J. Hassett, MD, MPH Instructor in Medicine, Harvard Medical School; Medical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
	Kevin S. Hughes, MD Associate Professor of Surgery, Harvard Medical School; Surgical Oncologist, Massachusetts General Hospital Cancer Center
	J Dirk Iglehart, MD Anne E. Dyson Professor of Women’s Cancers, Harvard Medical School; Director, Women’s Cancers Program, Dana-Farber Cancer Institute
	Steve Isakoff, MD, PhD Instructor in Medicine, Harvard Medical School; Medical Oncologist, Massachusetts General Hospital Cancer Center
	Ian E. Krop, MD, PhD Assistant Professor of Medicine, Harvard Medical School; Medical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
	Melinda J. Lerwill, MD Assistant Professor of Pathology, Harvard Medical School; Staff Pathologist, Massachusetts General Hospital
	Jennifer A. Ligibel, MD Instructor in Medicine, Harvard Medical School; Medical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
	Nancy U. Lin, MD Assistant Professor of Medicine, Harvard Medical School; Medical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
	Georgia Litsas, MSN, RN, NP Nurse Practitioner, Gillette Center for Women’s Cancers, Dana-Farber/Brigham and Women’s Cancer Center
	Shannon M. MacDonald, MD Assistant Professor of Radiation Oncology, Harvard Medical School; Radiation Oncologist, Massachusetts General Hospital Cancer Center
	Erica L. Mayer, MD, MPH Instructor in Medicine, Harvard Medical School; Medical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
	Jennifer McKenna, RN, MSN, AOCNP Nurse Practitioner, Gillette Center for Women’s Cancers, Dana-Farber/Brigham and Women’s Cancer Center
	Beth Overmoyer, MD, FACP Assistant Professor of Medicine, Harvard Medical School; Medical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
	Kornelia Polyak, MD, PhD Associate Professor of Medicine; Medical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
	Ann H. Partridge, MD, MPH Assistant Professor of Medicine, Harvard Medical School; Clinical Director, Breast Oncology Center, Dana-Farber/Brigham and Women’s Cancer Center; Director, Program for Young Women with Breast Cancer, Dana-Farber Cancer Institute
	Rinaa Punglia, MD, MPH Assistant Professor of Radiation Oncology, Harvard Medical School; Radiation Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
	Elizabeth Rafferty, MD Professor of Radiology, Harvard Medical School
	Andrea Richardson, MD, PhD Assistant Professor of Pathology, Harvard Medical School; Staff Pathologist, Brigham and Women’s Hospital
	Kathryn Ruddy, MD, MPH Instructor in Medicine, Harvard Medical School; Medical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
	Paula D. Ryan, MD, PhD Assistant Professor of Medicine, Harvard Medical School; Medical Director, Breast and Ovarian Cancer Genetics and Risk Assessment Program, Massachusetts General Hospital Gillettee Center for Breast Cancer
	Lidia Schapira, MD Associate Professor of Medicine, Harvard Medical School; Medical Oncologist, Massachusetts General Hospital Cancer Center
	Deborah Schrag, MD Associate Professor of Medicine, Harvard Medical School; Medical Oncologist, Center for Outcome Policy and Research, Dana-Farber/Brigham and Women’s Cancer Center
	Daniel P. Silver, MD, PhD Assistant Professor of Medicine, Harvard Medical School; Medical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
	Barbara Smith, MD, PhD Associate Professor of Surgery Harvard Medical School; Director, Gillette Center for Breast Cancer, Massachusetts General Hospital Cancer Center
	Michelle C. Specht, MD Instructor in Surgery, Harvard Medical School; Assistant in Surgery, Massachusetts General Hospital Cancer Center
	Sara M. Tolaney, MD, MPH Instructor in Medicine, Harvard Medical School; Medical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
	Susan Troyan, MD Instructor in Surgery, Harvard Medical School; Surgical Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
	Eric P. Winer, MD Professor of Medicine, Harvard Medical School; Thompson Senior Investigator and Chief, Division of Women’s Cancers, Dana-Farber Cancer Institute
	Julia Wong, MD Assistant Professor of Radiation Oncology, Harvard Medical School; Radiation Oncologist, Dana-Farber/Brigham and Women’s Cancer Center
	Erin Yeh, MD Assistant Professor of Radiology, Harvard Medical School; Radiologist, Dana-Farber/Brigham and Women’s Cancer Center
	Jerry Younger, MD Assistant Professor of Medicine, Harvard Medical School; Medical Oncologist, Massachusetts General Hospital Cancer Center
Guest Faculty
	Giuseppe Curigliano, MD, PhD Senior Deputy Director, Division of Medical Oncology, European Institute of Oncology IEO, Milan, Italy
	Susan Domchek, MD Associate Professor of Medicine; Director of the MacDonald Cancer Risk Evaluation Program, Senior Fellow, Leonard David Institute of Health Economics, University of Pennsylvania, Abramson Cancer Center
	Matthew Ellis, MD Professor, Department of Medicine, Washington University; Director, Breast Health Program, Washington University and Barnes-Jewish Hospital; Co-Director, Clinical and Translational Research, Siteman Comprehensive Cancer Center
	Laura J. Esserman, MD, MBA Professor, Surgery and Radiology, and Affiliate Faculty, Institute for Health Policy Studies, University of California at San Francisco; Director, Carol Franc Buck Breast Care Center; Co-Leader, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center
	Alain Fourquet, MD, Institut Curie William J. Gradishar, MD Professor of Medicine, Northwestern University Feinberg School of Medicine; Director, Breast Medical Oncology, Program Director, Hematology/Oncology Fellowship Program, Robert H. Lurie Comprehensive Cancer Center
	Julie Gralow, MD Professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine; Director of Breast Medical Oncology at Seattle Cancer Care Alliance.
	Lyndsay N. Harris, MD Associate Professor Yale University School of Medicine; Co-Director, Breast Cancer Program, Yale-New Haven Hospital
	Charles L. Loprinzi, MD Regis Professor of Breast Cancer Research, Mayo Clinic; Rochester, MN
	Funda Meric-Bernstam, MD Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas M. D. Anderson Cancer Center
	Monica Morrow, MD, FACS Chief, Breast Surgical Service, Anne Burnett Windfohr Chair of Clinical Oncology, Professor of Surgery, Weill Medical College of Cornell University
	C. Kent Osbourne, MD Director, Dan L. Duncan Cancer Center, Director, Lester and Sue Smith Breast Center, Professor of Medicine and Molecular and Cellular Biology, Dudley and Tina Sharp Chair for Cancer Research, Baylor College of Medicine
	Andrew Tutt, MB, ChB, PhD, MRCP, FRCR Consultant Clinical Oncologist/Director, Breakthrough Breast Cancer Research Unit, Research Oncology, Kings Health Partners, London, UK
	Ellen Warner, MD, FRCPC, FACP, MSc Associate Scientist, Sunnybrooke Health Sciences Centre, Toronto

Last update 04.13.10